Clinical trials: filgrastim
Healthy Volunteers
A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects
Phase 1, open-label, parallel, active-controlled, multiple IV dose, proof of concept study conducted at one study center in the United States (US).
- Trial name
- NCT02703051
- Testing
- GMI-1271, Filgrastim
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- GlycoMimetics Incorporated
Prostate Cancer Metastatic
Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel
The purpose of this study is to evaluate the incidence of grade ≥ 3 neutropenia and/or neutropenic complications (febrile neutropenia, neutropenic infection) with two schedules of cabazitaxel (bi-weekly versus tri-weekly) plus…
- Trial name
- CABASTY (NCT02961257)
- Testing
- cabazitaxel, Prednisone, Granulocyte colony-stimulating factor (G-CSF)
- Where
- 31 sites in France, Germany
- Volunteers
- 196 people
- Sponsor
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Burkitt Lymphoma
Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
This phase II trial is studying how well rituximab together with ifosfamide, carboplatin, and etoposide works in treating young patients with recurrent or refractory non-Hodgkin's lymphoma or acute lymphoblastic leukemia.
- Conditions
- B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma
- Trial name
- NCT00058461
- Testing
- ifosfamide, etoposide, rituximab
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining gemcitabine with docetaxel may kill more tumor cells.
- Trial name
- NCT00073983
- Testing
- filgrastim, pegfilgrastim, docetaxel
- Volunteers
- 54 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Breast Cancer
Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Currently patients with breast cancer are treated with one of several very similar combinations of drugs.
- Trial name
- NCT00017095
- Testing
- filgrastim, cyclophosphamide, docetaxel
- Where
- 39 sites in Belgium, France and 7 more
- Volunteers
- 1,856 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
This phase I trial studies the best dose of copanlisib when given together with combination chemotherapy (R-GCD) in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to…
- Conditions
- Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04156828
- Testing
- Copanlisib, Gemcitabine, Carboplatin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Hodgkin's Lymphoma
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
Objectives: Primary objective: Phase-I: To determine the maximal tolerated dose (MTD) of panobinostat (LBH589) + Ifosfamide + Mesna, Carboplatin and Etoposide (ICE) combination Randomized Phase-II: To estimate the complete…
- Trial name
- NCT01169636
- Testing
- Panobinostat, Ifosfamide, Mesna
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myelocytic, Acute
Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)
The AML-03 regimen investigates the addition of G-CSF priming to both induction and consolidation chemotherapies administrated in the previous AML-99 trial (NCT01716793) refines risk-stratification based on biological…
- Trial name
- NCT01723657
- Testing
- Ara-C, Autologous peripheral blood stem cell transplantation., Allogeneic matched related or unrelated donor transplant.
- Where
- 21 sites in Spain
- Volunteers
- 862 people
- Sponsor
- Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Acute Ischemic Stroke
AXIS 2: AX200 for the Treatment of Ischemic Stroke
The purpose of this study is to assess the efficacy of AX200 (filgrastim) in the treatment of acute ischemic stroke and to assess the safety and tolerability of AX200.
- Trial name
- AXIS-2 (NCT00927836)
- Testing
- Filgrastim, Sodium chloride solution
- Where
- 58 sites in Austria, Belgium and 5 more
- Volunteers
- 328 people
- Sponsor
- Sygnis Bioscience GmbH & Co KG
Stem Cell Transplant Patients
Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant
Patients who have not had adequate blood count recovery post related or unrelated stem cell transplant will be given a "boost" of T-cell depleted, enriched stem cells to hopefully improve their blood counts.
- Trial name
- NCT01026987
- Testing
- G-CSF, AMD3100, Leukapheresis
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Washington University School of Medicine
Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
- Trial name
- NCT00074165
- Testing
- Rituxan, Cyclophosphamide, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- OHSU Knight Cancer Institute
Infertility, Frozen Embryo Transfer (FET)
Platelet-Rich Plasma vs. Granulocyte Colony-Stimulating Factor vs. Placebo and Outcomes in Frozen Embryo Transfer
The goal of this clinical trial is to assess the impact of using Platelet-Rich Plasma (PRP) vs. Granulocyte Colony-Stimulating Factor (GCSF) vs.
- Trial name
- NCT03945812
- Testing
- Granulocyte Colony Stimulating Factor, Platelet Rich Plasma Arm, Saline
- Where
- Egypt
- Volunteers
- 665 people
- Sponsor
- Wael Elbanna Clinic
Fallopian Tube Cancer, Ovarian Cancer
Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
RATIONALE: Giving chemotherapy before a peripheral stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00550784
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Volunteers
- 8 people
- Sponsor
- City of Hope Medical Center
Leukemia, Myelodysplastic Syndromes
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
RATIONALE: Giving chemotherapy, such as busulfan, fludarabine, and melphalan, before a donor umbilical cord blood stem cell transplant helps stop the growth of abnormal or cancer cells and prepares the patient's bone marrow for…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Childhood Acute Myeloid Leukemia in Remission, Recurrent Childhood Acute Myeloid Leukemia
- Trial name
- NCT00357565
- Testing
- filgrastim, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Prostate Cancer
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with peripheral stem cell transplantation may allow the doctor to give higher…
- Trial name
- NCT00003400
- Testing
- filgrastim, carmustine, cisplatin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Maryland, Baltimore
Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome
Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome
OBJECTIVES: I. Determine the induction of durable remission in patients with life-threatening systemic lupus erythematosus or antiphospholipid antibody syndrome treated with cyclophosphamide. II.
- Trial name
- NCT00010400
- Testing
- Cyclophosphamide, filgrastim
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Johns Hopkins University
Peripheral Stem Cell/Marrow Transplant
ACB A Randomized Study of 2.5ug/kg/Day vs. 5ug/kg/Day Dose of G-CSF After High Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell/Marrow Transplant Recipients FILE#17159
Evaluate recovery time on 2.5 mg/Kg/day dose of G-CSF versus 5 mg/Kg/day dose.
- Trial name
- NCT00168168
- Testing
- G-CSF/Filgrastim
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Alberta Health services
Multiple Myeloma and Plasma Cell Neoplasm
Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma
RATIONALE: Melphalan and colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood.
- Trial name
- NCT00008268
- Testing
- filgrastim, melphalan
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hematologic Malignancies
G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome
The purposes of this study are: To examine the engraftment rate in patients receiving in vivo T-cell-depleted G-CSF stimulated bone marrow from partially mismatched related donors.
- Trial name
- G-CSF PMRD (NCT00228813)
- Testing
- Granulocyte Colony Stimulating Factor
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Emory University
Sarcoma
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00742924
- Testing
- cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride
- Where
- 88 sites in United States, Australia and 2 more
- Volunteers
- 24 people
- Sponsor
- Children's Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.